非抗体支架药物面临的挑战与机遇
Challenges and opportunities for non-antibody scaffold drugs.
作者信息
Vazquez-Lombardi Rodrigo, Phan Tri Giang, Zimmermann Carsten, Lowe David, Jermutus Lutz, Christ Daniel
机构信息
Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia; The University of New South Wales, Faculty of Medicine, St Vincent's Clinical School, Darlinghurst, Sydney, NSW 2010, Australia.
University of San Diego, School of Business Administration, 5998 Alcala Park, San Diego, CA 92110, USA.
出版信息
Drug Discov Today. 2015 Oct;20(10):1271-83. doi: 10.1016/j.drudis.2015.09.004. Epub 2015 Sep 7.
The first candidates from the promising class of small non-antibody protein scaffolds are now moving into clinical development and practice. Challenges remain, and scaffolds will need to be further tailored toward applications where they provide real advantages over established therapeutics to succeed in a rapidly evolving drug development landscape.
来自前景广阔的小型非抗体蛋白支架类别的首批候选物目前正进入临床开发和实践阶段。挑战依然存在，并且支架需要进一步针对那些相较于现有疗法具有真正优势的应用进行定制，以便在快速发展的药物开发现状中取得成功。
Zotero 插件